SCHEMBL476443

SCHEMBL476443

COc1ccc(S(=O)(=O)c2cc(CO)nn2-c2cccnc2F)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 5/20 0.45
CA2 P00918 5/20 0.45
CA9 Q16790 5/20 0.45
MMP2 P08253 2/20 0.40
MMP9 P14780 2/20 0.40
MMP8 P22894 2/20 0.40
MMP13 P45452 2/20 0.40
NFE2L2 Q16236 3/20 0.38
HSD11B1 P28845 1/20 0.36
PKM P14618 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
NPY1R P25929 1/20 0.36
APLNR P35414 1/20 0.36
KEAP1 Q14145 1/20 0.36
PTGS2 P35354 1/20 0.35
PTGS1 P23219 1/20 0.35
GAA P10253 2/20 0.35
PTGDR2 Q9Y5Y4 1/20 0.35
USP2 O75604 1/20 0.35
ALDH1A1 P00352 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3703141 0.90 CA1 (0.44) CA1CA2CA9NFE2L2GAA
SCHEMBL476288 0.88 COMT (0.41) CA1CA2CA9NFE2L2PKM
SCHEMBL476372 0.88 MMP2 (0.37) MMP2MMP9MMP8MMP13NFE2L2
Hydrochloric Acid SCHEMBL476489 0.87 MMP2 (0.37) MMP2MMP9MMP8MMP13NFE2L2
SCHEMBL3694113 0.87 CA1 (0.40) CA1CA2CA9PTGS2PTGDR2
SCHEMBL476464 0.82 NFE2L2 (0.41) MMP2MMP9MMP8MMP13NFE2L2
SCHEMBL476363 0.82 HTR6 (0.39) CA1CA2CA9PKMPTGS2
SCHEMBL476502 0.82 TP53 (0.45) CA9MMP2MMP9MMP8MMP13
SCHEMBL476311 0.80 CA1 (0.35) CA1CA2CA9PTGS2
SCHEMBL4123859 0.80 CA1 (0.35) CA1CA2CA9PTGS2PTGDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2412713-B1 PYRAZOLE COMPOUND TAKEDA PHARMACEUTICAL (JP) 2016-11-30 EP disclosed
US-8895588-B2 Pyrazole compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-11-25 US disclosed
US-8895588-B2 Pyrazole compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-11-25 US disclosed
US-8895588-B2 Pyrazole compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-11-25 US disclosed
US-20120095057-A1 PYRAZOLE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-04-19 US disclosed
US-20120095057-A1 PYRAZOLE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-04-19 US disclosed
US-20120095057-A1 PYRAZOLE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-04-19 US disclosed
EP-2412713-A1 PYRAZOLE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2012-02-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095057-A1 PYRAZOLE COMPOUND CEL, HRH2, GIPR CA1 361/4885CA2 309/4885CA9 913/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.